UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36548 ATARA BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 46-0920988 (State or Other Jurisdiction o ...

Exhibit 99.1 Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress Tab-cel ® U.S. BLA on Track for Submission in Q2 2024 Initiation of ATA3219 Lupus Nephritis Study Expected in Q4 2024, with Initial Clinical Data Expected in H1 2025 Initiation of New ATA3219 Cohort Without Lymphodepletion in Severe Systemic Lupus Erythematosus Planned for Q4 2024, with Initial Clinical Data Expected in H2 2025 Enrolling ATA3219 Non-Hodgkin's Lymphoma Study, with Initial Clinical Data ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share, ATRA The Nasdaq Stock Market LLC FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm ...

Exhibit 99.1 Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress Tab-cel U.S. BLA on Track for Submission in Q2 2024 Following Positive Pre-BLA Meeting Allogeneic CAR T Pipeline Expands Into Autoimmune Disease With Plans To Initiate a ATA3219 Lupus Nephritis Study in H2 2024, and Initial Clinical Data Expected H1 2025 ATA3219 NHL Study Enrolling With Initial Clinical Data Expected in Q4 2024 Cash Runway Into 2027 Enables Key Pipeline Readouts | --- | ...

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for ATA3219, an allogeneic, anti-CD19 chimeric antigen receptor (CAR) T-cell monotherapy for the treatment of systemi ...

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced its recent submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the use of ATA3219 as a monotherapy for the treatment of systemic lupus erythematosus (SLE) with ...

Jordan Lye/Moment via Getty Images Topline Summary Atara Biotherapeutics (NASDAQ:ATRA) is a commercial-stage biotech focused on the development and commercialization of cell therapies for patients with Epstein-Barr virus infection associated diseases and cancer. While they had a prominent trial failure late last year, they are generating revenues and improving their cash runway all the time. I'm rating this a buy because there is a lot of potential for valuation appreciation if they can remove some of t ...

 First Phase 3 Results Published for an Allogeneic T-Cell Therapy Significant 51.2% Objective Response Rate and 23.0 Month Median Duration of Response in Relapsed or Refractory EBV+ PTLD Patients U.S. BLA on Track for Submission in Q2 2024 Based on Strong Clinical File CASTRES, France and THOUSAND OAKS, Calif., Feb. 1, 2024 /PRNewswire/ -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transfo ...

THOUSAND OAKS, Calif. & CASTRES, France--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, and Pierre Fabre Laboratories, a global player in oncology and responsible for worldwide commercialization of tabelecleucel (tab-cel® or EBVALLO™), today announced that data from the pivotal Phase 3 ALLELE study of ta ...

Core Viewpoint - Atara Biotherapeutics, Inc. has announced a definitive agreement for the issuance and sale of pre-funded warrants to purchase 27,272,727 shares of its common stock at a price of $0.55 per share, aiming to raise approximately $15 million in gross proceeds for working capital and general corporate purposes [1][2]. Group 1: Offering Details - The pre-funded warrants will have an exercise price of $0.0001 per share and will be immediately exercisable upon issuance [1]. - The offering is expected to close on or about January 10, 2024, subject to customary closing conditions [1][2]. - The securities are being offered under a shelf registration statement previously filed with the SEC, which was declared effective on November 13, 2023 [2]. Group 2: Company Overview - Atara Biotherapeutics is focused on T-cell immunotherapy, utilizing its allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for cancer and autoimmune diseases [1][4]. - The company is recognized for being the first to receive regulatory approval for an allogeneic T-cell immunotherapy, highlighting its innovative approach in the field [4]. - Atara's EBV T-cell platform does not require T-cell receptor or HLA gene editing, allowing for a diverse portfolio of investigational therapies targeting EBV and next-generation AlloCAR-Ts [4].